英語得意な方訳して

毎日のようにくるメールです。なんて書いてるかわかりません。

FTC@100 Banner
FTC Action Stops Unsupported Claims for Opiate Withdrawal Treatments
Defendants claimed herbal products alleviated symptoms of opiate withdrawal and helped users overcome opiate dependency

A company that marketed itself as “the leader in home opiate detox since 2009” and its CEO have settled Federal Trade Commission charges that the withdrawal treatment claims for their “Withdrawal Ease” and “Recovery Ease” products were false or unsupported by scientific evidence.

The court order settling the FTC’s charges bars Catlin Enterprises, Inc. and George Catlin, based in Austin, Texas, from making claims about opiate withdrawal, opiate dependency, or other health conditions, including through their product names, unless they possess competent and reliable science to back up those claims.

“Opioid addiction is a scourge that has affected millions of Americans,” said Acting FTC Chairman Maureen K. Ohlhausen. “People who struggle with this problem need real help, not phony claims and false promises like the ones peddled by these defendants.”

According to the FTC’s complaint, the defendants violated the FTC Act by making unsubstantiated claims that Withdrawal Ease: 1) significantly alleviated the symptoms of opiate withdrawal; and 2) significantly increased the likelihood of a person overcoming opiate dependency. The defendants also allegedly misrepresented that clinical studies proved Withdrawal Ease’s effectiveness. The complaint charges the defendants with deceptively representing that Recovery Ease significantly alleviated long-term opiate withdrawal symptoms.